We appreciate the correspondence from D. Monneret regarding the issue of analytical precision for troponin assays in the low range of concentrations, and thus the limitations in the interpretation of small decrements in troponin levels. In our study, serum biomarkers were secondary endpoints [1], and the findings and clinical significance of the lowering of troponin levels in the low range of concentrations certainly warrant further delineation in studies specifically targeting the possibility of subclinical myocardial injury in a group of high cardiovascular risk patients, and correlating any biochemical change with functional tests such as cardiac imaging. Regarding potential lot-to-lot variation of the troponin assay, the study samples were tested in batch assay, and paired pre- and post-CPAP samples were analysed in the same lot.

我们感谢 D. Monneret 就低浓度范围内肌钙蛋白测定的分析精度问题的通信，以及因此对肌钙蛋白水平小幅下降的解释的局限性。在我们的研究中，血清生物标志物是次要终点 [1]，在低浓度范围内降低肌钙蛋白水平的发现和临床意义当然值得在专门针对一组高浓度患者亚临床心肌损伤可能性的研究中进一步描述。心血管风险患者，并将任何生化变化与心脏成像等功能测试相关联。关于肌钙蛋白测定的潜在批次间差异，研究样品在批次测定中进行了测试，并在同一批次中分析了成对的 CPAP 前后样品。